Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension
NCT05549726Phase 4Completed
- Sponsor
- University of California, San Francisco
- Start
- Jan 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial in human immunodeficiency virus infection (HIV) comparing Dynamic choice prevention (including CAB LA) with Standard of Care (2 arms). Primary endpoint: Proportion of time covered by a biomedical prevention product at 48 weeks. Started Jan 2023; status: completed.
02
Drugs
cabotegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05549726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549726.